Xlife Sciences AG / Key word(s): AGMEGM
Xlife Sciences AG (SIX: XLS) today published the agenda of its upcoming Ordinary Annual General Meeting 2023 that will take place on Tuesday, June 20, as of 10 am CET at Hotel “Schweizerhof” in Zurich, Switzerland:
Oliver R. Baumann, CEO and member of the Board of Directors of Xlife Sciences, comments: “We are looking forward to the interaction with our shareholders on June 20 in Zurich. On behalf of all members of the Xlife Group, I would like to thank Bernhard Scholz already today for his extraordinary contribution and tireless efforts over the past four years. At the same time, we thank David L. Deck for making himself available as new Chairman. As founder and major shareholder, he will bring valuable and relevant skills and perspectives”.
Xlife Sciences today also provided an update on the ongoing divestment of its stake in the portfolio company Laxxon Medical. In the last weeks, the Company sold additional around 15% of its Laxxon Medical shares, generating proceeds of CHF 1.5 million. Thus, since March 2023 Xlife Sciences divested around 46% of its shares in Laxxon Medical, generating proceeds of around CHF 4.5 million.
Annual General Meeting 2023 June 20, 2023
Half-Year Report 2023 September 21, 2023
Information for journalists: IRF Reputation AG, Valentin Handschin, email@example.com
Information for investors: Xlife Sciences AG, Carl v. Halem, firstname.lastname@example.org
Xlife Sciences AG
End of Inside Information
|Company:||Xlife Sciences AG|
|Phone:||+41 44 385 84 60|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1642479|
|End of Announcement||EQS News Service|
1642479 26-May-2023 CET/CEST